Year: 2017
Type: review
Abstract: Accompanied by the growing clinical applications of immunotherapy in the treatment of cancer patients, development of novel therapeutic approaches to reverse the immune-suppressive environment in cancer patients is eagerly anticipated, because the success of cancer immunotherapy is currently limited by immune-suppressive effects in tumor-bearing hosts. Interleukin (IL)-6, a pleotropic proinflammatory cytokine, participates in tumor cell-autonomous processes that are required for their survival and growth, and is therefore known as a poor prognostic factor in cancer patients. In addition, an emerging role of IL-6 in modulating multiple functions of immune cells including T cells, dendritic cells, and macrophages is responsible for the dysfunction of innate and adaptive immunity against tumors. Therefore, the IL-6-targeting approach is of value as a promising strategy for desensitization and prevention of immune-suppressive effects, and should be an effective treatment when combined with current immunotherapies. The aim of the present review is to discuss the immune-suppressive aspects of IL-6, notably with modification of T-cell functions in cancer patients, and their relationship to anti-tumor immune responses and cancer immunotherapy.
Source: Cancer Science
DOI: 10.1111/cas.13433
Language: English
Subfield: Immunology
Field: Immunology and Microbiology
Domain: Life Sciences
Open Access status: gold
Estimated APC paid: $2,600
Awards: G1650677228, Novel interaction between virus and host innate immune system, Development of novel cancer immunotherapeutic approach based on age-associated inflammatory response, Development of cancer immunotherapy using tumor-associated antigen-derived long peptides and liberation from immune suppression mediated trough IL-6 signaling, G43627889, The detrimental effect of soluble IL-6 receptor on CD4 T cell-mediated anti-tumor immune responses
OpenAlex ID: W2766225245
